[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Methodist Health System\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":470},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,26,0,25,[9,40,59,75,92,109,129,147,164,182,201,219,237,253,267,284,303,319,337,356,375,396,416,435,454],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100643063","psychosocial-burden-and-quality-of-life-in-caretakers-of-hepatobiliary-cancer-patients-100643063",false,"NCT07644091","Psychosocial Burden and Quality of Life in Caretakers of Hepatobiliary Cancer Patients","Psychosocial Burden and Quality of Life in Caretakers of Hepatobiliary Cancer Patients: A Survey-Based Analysis","Inclusion Criteria:\n\nCaretakers must be aged 18 years or older at the time of the survey Participants must be a family member or caretaker of an individual who is diagnosed with hepatobiliary cancer and is receiving care at the Methodist Cancer Center in Richardson, Texas. Diagnosis should be made within 2 years and is non-recurrent in nature. Participants must be an English speaker.\n\nExclusion Criteria:\n\nThis study is intended to assess the burden and well-being of unpaid caretakers of hepatobiliary cancer patients. Thus, paid caretakers, such as home health aides, will be excluded from the survey.",true,"ALL","18 Years",{"count":21,"type":22},150,"ESTIMATED","OBSERVATIONAL","Assess caregiver psychosocial burden, including Quality of Life, health, interpersonal relationship, access to support, and explore associated sociodemographic and contextual factors.",[26],"Psychosocial Problem","RECRUITING","2026-06-08",{"date":30,"type":31},"2026-06-12","ACTUAL",{"date":33,"type":31},"2026-05-26",{"date":35,"type":22},"2028-05",{"name":37,"class":38},"Methodist Health System","OTHER",1,{"id":41,"slug":42,"hasResults":12,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":52,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":39},"100636420","evaluation-of-hepato-pancreato-biliary-100636420","NCT07565454","Evaluation of Hepato-Pancreato-Biliary","Evaluation of HPB or Advanced GI Surgery Fellowship Training","Inclusion Criteria:\n\n1. Current, and past fellows of Fellowship Council(FC )sponsored fellowship including Americas Hepato-Pancreato-Biliary Association(AHPBA)-accredited HPB and Advanced GI surgery fellowship.\n2. Current senior surgeons involved in Fellowship Council(FC) fellowship training.\n\nExclusion Criteria:\n\nFellows who choose not to respond to the survey",{"count":48,"type":22},100,"Some reports cite over 80% of surgery residency graduates are seeking additional training to improve on their experiences to be ready for practice. The Fellowship Council created several fellowship tracts including HPB (Hepato-Pancreato-Biliary),Advanced GI (gastrointestinal) and Minimally Invasive surgery to address this issue, and bridge the gap in training between residency and real life practice in those that seek a practice in HPB or complex GI surgery, respectively. By the end of fellowship, the core goal is to make the graduating fellows ready for independent practice in HPB or complex GI surgery cases.",[51],"Gastro-Intestinal Disorder",{"date":53,"type":31},"2026-06-10",{"date":55,"type":31},"2021-04-01",{"date":57,"type":22},"2028-01",{"name":37,"class":38},{"id":60,"slug":61,"hasResults":12,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":68,"conditions":69,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":70,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":74,"locationsCount":39},"100630949","advanced-gastroinstestinalgi-surgery-training-in-residency-and-fellowship-100630949","NCT07494318","Advanced GastroInstestinal(GI) Surgery Training in Residency and Fellowship.","Advanced GastroInstestinal(GI) Surgery Training in Residency and Fellowship Interest Survey for 4th and 5th Year General Surgical Residents.","Inclusion Criteria:\n\nAll fourth and fifth year general surgery residents in accredited Accreditation Council for Graduate Medical Education(ACGME) general surgery residency programs in the United States.\n\nExclusion Criteria:\n\nAll junior general surgical residents (third year residents through interns) will be excluded from the study.",{"count":67,"type":22},260,"The aim of this anonymous survey is to identify who teaches GI procedures to general surgical residents during residency training and understand the need as well as desire for an Advanced Surgical GI fellowship amongst senior surgical residents. We also hope to identify the self-reported level of comfort of senior general surgery residents in completing both common and complex GI procedures.",[51],{"date":53,"type":31},{"date":72,"type":31},"2018-08-02",{"date":57,"type":22},{"name":37,"class":38},{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":82,"targetDuration":83,"studyType":23,"phases":4,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":91,"locationsCount":39},"100630629","enteric-anastomoses-100630629","NCT07490158","Enteric Anastomoses","Enteric Anastomoses in Trauma","Inclusion Criteria:\n\n18 years old Included in the MDMC(Methodist Dallas Medical Center) Trauma Registry Any diagnosis code indicative of injury to the large and\u002For small bowel (S36.5 and\u002For S36.4)\n\nExclusion Criteria:\n\n\\\u003C18 years old Prisoners, pregnant persons, or other protected population.",{"count":48,"type":22},"5 Years","This retrospective data repository will serve as a means to aggregate and analyze best practices as relative to traumatic colon injury outcomes.",[86],"Trauma",{"date":53,"type":31},{"date":89,"type":31},"2024-02-16",{"date":57,"type":22},{"name":37,"class":38},{"id":93,"slug":94,"hasResults":12,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":103,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":39},"100533268","dual-antiplatelet-therapy-dapt-in-patients-with-baseline-thrombocytopenia-100533268","NCT06223607","Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia","Inclusion Criteria:\n\n* ≥ 18 years\n* PCI with either DES or BMS during study time period (April 1, 2018 through July 1 2021)\n* Thrombocytopenia defined as platelet count \\\u003C100 x103 \u002FµL on at least one occasion prior to PCI\n* At least one dose of DAPT post-PCI with aspirin and either clopidogrel or ticagrelor\n\nExclusion Criteria:\n\n* Death within 48 hours post-PCI\n* DAPT prior to cardiac catheterization",{"count":99,"type":22},300,"The use of clopidogrel as part of DAPT will be associated with lower bleeding rates compared to ticagrelor in patients with chronic thrombocytopenia requiring Percutaneous intervention (PCI )with Drug Eluting Stent (DES) or Bare Metal Stint(BMS).",[102],"Baseline Thrombocytopenia",{"date":53,"type":31},{"date":105,"type":31},"2022-08-22",{"date":107,"type":22},"2027-12-22",{"name":37,"class":38},{"id":110,"slug":111,"hasResults":12,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":117,"phases":118,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":123,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":39},"100533270","pkpharmacokinetic-papyrus-covered-coronary-stent-system-100533270","NCT06223633","PK(Pharmacokinetic) Papyrus Covered Coronary Stent System","Inclusion Criteria:\n\n* Patients with acute perforations of native coronary arteries and coronary bypass grafts in vessels 2.5 to 5.0 mm in diameter\n\nExclusion Criteria:\n\n* Patients in whom antiplatelet agents or anticoagulation therapy is contraindicated.\n* Patients with a known allergy or hypersensitivity to amorphous silicon carbide or any other compound of the system (siloxane-based polyurethane, L-605 cobalt chromium alloy including tungsten and nickel).\n* Lesions that cannot be reached or treated with the system.\n* Lesions with threatened or abrupt closure during attempted pre-dilation prior to stent implantation.\n* Risk of treatment-related occlusion of vital coronary artery side branches.\n* Uncorrected bleeding disorders.\n* Allergy to contrast media.",{"count":116,"type":22},41,"INTERVENTIONAL",[119],"NA","The PK Papyrus Covered Coronary Stent System is a coronary stent being used at Methodist Dallas Medical Center for patients with coronary perforations.",[122],"Coronary Disease",{"date":53,"type":31},{"date":125,"type":31},"2023-08-10",{"date":127,"type":22},"2028-08",{"name":37,"class":38},{"id":130,"slug":131,"hasResults":12,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":141,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":39},"100411684","peroral-endoscopic-myotomy-for-the-treatment-of-achalasia-100411684","NCT04640753","Peroral Endoscopic Myotomy for the Treatment of Achalasia","Peroral Endoscopic Myotomy for the Treatment of Achalasia: A Single-center Registry","Inclusion Criteria:\n\n* Any discharged patient who has undergone clinically indicated and\u002For standard of care POEM for the treatment of Achalasia from 6\u002F2016 to 6\u002F2021.\n* Above or equal to 18 years of age\n\nExclusion Criteria:\n\n* Any patient who has not undergone POEM for the treatment of Achalasia.\n* Below 18 years of age",{"count":137,"type":22},200,"There will be a retrospective chart review for patients who underwent endoscopic procedures and POEM from 06\u002F2016 - 01\u002F2019 \\& a prospective chart review will be performed for patients who will undergo endoscopic procedures and POEM from 02\u002F2019 - 06\u002F2021",[140],"Achalasia",{"date":53,"type":31},{"date":143,"type":31},"2019-02-06",{"date":145,"type":22},"2027-02-05",{"name":37,"class":38},{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":158,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":39},"100366769","evaluation-of-outcomes-from-treatment-of-benign-or-malignant-pancreatic-diseases-100366769","NCT04055571","Evaluation of Outcomes From Treatment of Benign or Malignant Pancreatic Diseases","Inclusion Criteria:\n\n* • All patients diagnosed and treated for pancreatic diseases, benign or malignant from 2005 to present\n\n  * Age ≥18 years\n\nExclusion Criteria:\n\n* • Patients that are not diagnosed with or treated for pancreatic diseases\n\n  * Age \\\u003C 18 years",{"count":154,"type":22},500,"This study will be a retrospective chart review of patients who have been diagnosed with the benign or malignant pancreatic disease under the practice of Dr. Rohan Jeyarajah, M.D., Dr. Houssam Osman M.D., and Dr. Edward Cho M.D., Sc.M. at Methodist Health System Hospital in Richardson, Texas(TX). The investigators plan to conduct an analysis of patients meeting the inclusion criteria from 2005 to present. Study will also be conducted by the PI, Sub-Is, surgery fellows, office staff and clinical research coordinator who are delegated to do by the PI. Data will be obtained by looking through either investigator's patients or through a national database. Data will be analyzed primarily by the study conductors.",[157],"Benign or Malignant Pancreatic Diseases",{"date":53,"type":31},{"date":160,"type":31},"2019-03-05",{"date":162,"type":22},"2028-01-30",{"name":37,"class":38},{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":39},"100533390","exploratory-analysis-of-enhanced-liver-function-elf-test-to-detect-early-fatty-liver-in-high-risk-population-100533390","NCT06225193","Exploratory Analysis of Enhanced Liver Function (ELF) Test to Detect Early Fatty Liver in High Risk Population","Inclusion Criteria:\n\n* Age: ≥ 18 years\n* NAFLD\u002FNASH and non-NAFLD\u002FNASH patients who have had an assessment with ELF score at Methodist Dallas Medical Center from November 2021 to December 2023.\n\nExclusion Criteria:\n\n* Patients with incomplete data and those lost to follow up.",{"count":99,"type":22},"In this initial investigator-initiated retrospective study, aim to analyze the enhanced liver fibrosis (ELF) scores in this high-risk population for NAFLD\u002Fnonalcoholic steatohepatitis(NASH)-related fibrosis. Study define 'high-risk' to include metabolic syndrome, which can be further defined by an atherosclerotic cardiovascular disease (ASCVD) score \\>7.5, any diagnosis of hyperlipidemia, history of coronary artery disease, history of heart failure, hypertension and\u002For type 2 diabetes. Study would also like to compare the performance of this score with historical methods of fibrosis assessment, where applicable, including vibration-controlled transient elastography, magnetic resonance elastography, blood markers and liver biopsy. Study will assess the impact of ELF scores on predicting liver events in the time, have used it and determine if diet, lifestyle changes and\u002For pharmacotherapy will improve serial ELF scores. Will also seek to understand how ELF scores are distributed in our community.",[173],"Fatty Liver","2026-05-11",{"date":176,"type":31},"2026-05-13",{"date":178,"type":31},"2023-06-20",{"date":180,"type":22},"2026-06-23",{"name":37,"class":38},{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":12,"sex":18,"minAge":189,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":200,"locationsCount":39},"100635987","early-onset-colorectal-cancer-patients-too-young-for-screening-100635987","NCT07559825","Early-Onset Colorectal Cancer Patients Too Young for Screening","Early-Onset Colorectal Cancer Patients Too Young for Screening: Outcomes and Treatment Patterns","Inclusion Criteria:\n\n* Colorectal cancer\n\nExclusion Criteria:\n\n* No Colorectal cancer","35 Years",{"count":48,"type":22},"This is a population-based retrospective study using the Surveillance, Epidemiology, and End Results (SEER) registry and National Cancer Data Base (NCDB) to look at colorectal cancer (CRC) patients younger than 35 and comparing them against CRC patients older than 35 years of age.",[193],"Colorectal Cancer","2026-04-27",{"date":196,"type":31},"2026-04-30",{"date":198,"type":31},"2020-01-31",{"date":57,"type":22},{"name":37,"class":38},{"id":202,"slug":203,"hasResults":12,"nctId":204,"briefTitle":205,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":209,"conditions":210,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":39},"100523419","a-retrospective-analysis-of-outcomes-in-patients-with-hepatorenal-syndrome-at-methodist-dallas-medical-center-100523419","NCT06095440","A Retrospective Analysis of Outcomes in Patients With Hepatorenal Syndrome at Methodist Dallas Medical Center","Inclusion Criteria:\n\n* All patients \\>18 years old that were hospitalized between April 1st 2019 and April 1st 2023 who either presented with HRS-AKI or developed a diagnosis of HRS during the hospital course. HRS-AKI will be defined based on the ICA criteria, described below:\n\n  1. Presence of cirrhosis, acute liver failure, or acute-on-chronic liver failure\n  2. An increase in serum Cr of ≥0.3 mg\u002FdL within 48 hours or ≥50% from baseline value and\u002For urinary output ≤0.5 mL\u002Fkg of body weight for ≥6 hours (requires use of a urinary catheter)\n  3. No full or partial response for ≥2 days of diuretic withdrawal and volume expansion with albumin (dosed at 1 g\u002Fkg of body weight\u002Fday)\n  4. Absence of shock\n  5. No current or recent treatment with nephrotoxic drugs\n  6. Absence of parenchymal renal disease\n  7. Suggestion of renal vasoconstriction based on FENa \\\u003C0.2%\n\nExclusion Criteria:\n\n* 1\\. HRS-AKI patients \\\u003C18 years of age 2. All patients hospitalized between April 1st 2019 and April 1st 2023 without a diagnosis of HRS-AKI.","85 Years",{"count":154,"type":22},"Hepatorenal syndrome (HRS) is a common cause of acute kidney injury (AKI) in patients with liver disease \\[1\\]. Increased activity and presence of vasodilators such as nitric oxide in cirrhotic patients leads to vasodilation, especially in the splanchnic circulation, resulting in hemodynamic changes that precipitate renal injury \\[1\\]. Patients may present with elevated serum creatinine (Cr), benign urine sediment, and low urine sodium \\[1\\].",[211],"Hepatorenal Syndrome",{"date":213,"type":31},"2026-05-01",{"date":215,"type":31},"2023-05-13",{"date":217,"type":22},"2027-05-13",{"name":37,"class":38},{"id":220,"slug":221,"hasResults":12,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":226,"targetDuration":83,"studyType":23,"phases":4,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":39},"100630630","traumatic-cardiac-arrest-100630630","NCT07490171","Traumatic Cardiac Arrest","Traumatic Cardiac Arrest Registry","Inclusion Criteria:\n\n≥18 years old Included in the MDMC Trauma Registry Cardiac arrest in pre-hospital setting or trauma bay\n\nExclusion Criteria:\n\n\\\u003C18 years old Prisoners, pregnant persons, or other protected population",{"count":48,"type":22},"This retrospective data repository will serve as a means to aggregate and analyze order of pre-hospital care (intubation, medication, etc) as it relates to Traumatic cardiac arrest.",[86],"2026-03-18",{"date":231,"type":31},"2026-03-24",{"date":233,"type":22},"2026-02",{"date":235,"type":22},"2028-02",{"name":37,"class":38},{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":12,"sex":18,"minAge":244,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":246,"conditions":247,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":249,"startDateStruct":250,"completionDateStruct":251,"leadSponsor":252,"locationsCount":39},"100630631","cardiac-clearance-vs-g60-hip-frailty-index-100630631","NCT07490184","Cardiac Clearance vs G60 Hip Frailty Index","Cardiac Clearance vs G60 Hip Frailty Index in Trauma","Inclusion Criteria:\n\n≥60 years old Included in the Methodist Dallas Medical Center Trauma Registry Documented orthopedic injury with surgical management\n\nExclusion Criteria:\n\n\\\u003C60 years old Prisoners, pregnant persons, or other protected populations","60 Years",{"count":48,"type":22},"The primary objective of this study is to establish a data repository that will be permissive of quality improvement studies\u002Fobservations specific to postoperative mortality outcomes for geriatric patients with orthopedic injuries based on Orthopedic Hip Frailty Score and preoperative cardiac clearance predictors.",[248],"Cardiac Disease",{"date":231,"type":31},{"date":233,"type":22},{"date":235,"type":22},{"name":37,"class":38},{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":261,"conditions":262,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":263,"startDateStruct":264,"completionDateStruct":265,"leadSponsor":266,"locationsCount":39},"100630632","acute-subdural-hematoma-100630632","NCT07490197","Acute Subdural Hematoma","Acute Subdural Hematoma Registry","Inclusion Criteria:\n\n* ≥18 years old\n* Included in the Methodist Dallas Medical Center Trauma Registry\n* Acute subdural hematoma identified on computed tomography scan or magnetic resonance imaging of the brain in the trauma bay within 72 hours of a traumatic event\n\nExclusion Criteria:\n\n* \\\u003C18 years old\n* Prisoners, pregnant persons, or other protected population",{"count":48,"type":22},"This retrospective data repository will serve as a means to aggregate and analyze standard surgical interventions and Middle Meningeal Arteryembolization as suitable treatment options for Acute Subdural Hematoma.",[86],{"date":231,"type":31},{"date":233,"type":22},{"date":235,"type":22},{"name":37,"class":38},{"id":268,"slug":269,"hasResults":12,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":278,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":39},"100630628","trauma-activation-criteria-100630628","NCT07490145","Trauma Activation Criteria","Trauma Activation Criteria Refinement","Inclusion Criteria:\n\nPatient is included in the Methodist Dallas Medical Center trauma registry. Trauma patients who recieved care at Methodist Dallas Medical Center between November 24, 2023 and November 25, 2025.\n\nExclusion Criteria:\n\nPatient does not meet registry inclusion criteria.",{"count":275,"type":22},5000,"To quantify the over- and under-triage rates as relative to trauma activation criteria reform.",[86],{"date":231,"type":31},{"date":280,"type":31},"2024-11-24",{"date":282,"type":22},"2028-11",{"name":37,"class":38},{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":290,"targetDuration":292,"studyType":23,"phases":4,"briefSummary":293,"conditions":294,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":39},"100630337","evaluation-of-emergency-medicine-pharmacist-impact-on-blood-culture-review-following-emergency-department-discharge-100630337","NCT07486362","Evaluation of Emergency Medicine Pharmacist Impact on Blood Culture Review Following Emergency Department Discharge","Inclusion Criteria:\n\n* Patients with a positive blood culture result, collected during the initial ED visit and who were discharged from the ED to the outpatient\u002Flong-term care setting prior to a critical blood Groups culture result.\n\nExclusion Criteria:\n\n* Patients admitted to inpatient and patients transferred from ED to another acute care facility.",{"count":291,"type":22},126,"6 Months","Patients are commonly discharged from the Emergency Department(ED) with pending blood culture results. Blood cultures can take up to 48 hours to become positive which is why it is important to notify patients with true positive cultures as soon as possible. Delay in notification can lead to other serious complications such as sepsis, septic shock, and death.\n\nThe American College of Emergency Physicians states pharmacists serve a critical role in ensuring efficient, safe, and effective medication use in the ED and advocates for health systems to support dedicated roles for pharmacists within the ED. Pharmacists help to decrease the workload on the healthcare team, especially in the ED where there is high volume and acuity.Emergency medicine pharmacist (EMP) play a significant role in the optimization of therapy, medication safety, and reducing costs.\n\nThere is strong evidence for the positive impact EMPs have on microbiological culture review. Overall, pharmacist review of late cultures results in higher rates of appropriate antimicrobial therapy and decreased missed interventions.These prior studies focused on the review of microbiological tests, including sexually transmitted infections, urine, and wound cultures; however, there was limited data to support the role of pharmacists evaluating late blood culture results.",[295],"Bacteremia",{"date":297,"type":31},"2026-03-20",{"date":299,"type":31},"2024-01-31",{"date":301,"type":22},"2028-01-31",{"name":37,"class":38},{"id":304,"slug":305,"hasResults":12,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":12,"sex":18,"minAge":310,"maxAge":4,"enrollmentInfo":311,"targetDuration":312,"studyType":23,"phases":4,"briefSummary":313,"conditions":314,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":315,"startDateStruct":316,"completionDateStruct":317,"leadSponsor":318,"locationsCount":39},"100630627","endoscopic-retrograde-cholangiopancreatography-100630627","NCT07490132","Endoscopic Retrograde Cholangiopancreatography","Endoscopic Retrograde Cholangiopancreatography Patient Registry","Inclusion Criteria:\n\nPatients \\>15 years Included in MDI's Registry Underwent ERCP between January 1, 2000 through December 31, 2025\n\nExclusion Criteria:\n\nPatients \\\u003C15 years Patients in which cannulation was via a surgical anastomosis Patients in which cannulation was not attempted due to gastric outlet obstruction, the main papilla not found, or the minor papilla was not found will be excluded.","15 Years",{"count":48,"type":22},"25 Years","The risk of post-endoscopic retrograde cholangiopancreatography(ERCP) pancreatitis(PEP) is influenced by patient and procedure-related factors. Strategies to decrease PEP(Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis) are of great importance.",[51],{"date":231,"type":31},{"date":233,"type":22},{"date":235,"type":22},{"name":37,"class":38},{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":326,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":328,"conditions":329,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":331,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":39},"100542494","volume-outcome-relationships-and-effects-100542494","NCT06343597","Volume Outcome Relationships and Effects","Volume Outcome Relationships and Effects of Adjuvant and Neoadjuvant Therapy in Mortality in Esophageal Cancer","Inclusion Criteria:\n\n* esophageal cancer\n\nExclusion Criteria:\n\n* No esophageal cancer",{"count":327,"type":22},30,"This is a retrospective analysis to assess if high-volume hospital facilities experience greater or lesser rates of incidence in patients with esophageal cancer than low-volume facilities.",[330],"Esophageal Cancer",{"date":297,"type":31},{"date":333,"type":31},"2020-06-15",{"date":335,"type":22},"2028-06-15",{"name":37,"class":38},{"id":338,"slug":339,"hasResults":12,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":4,"eligibilityCriteria":343,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":344,"targetDuration":4,"studyType":117,"phases":345,"briefSummary":346,"conditions":347,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":350,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":39},"100533176","leadership-training-affect-physician-career-satisfaction-100533176","NCT06222411","Leadership Training Affect Physician Career Satisfaction","Does Leadership Training Affect Physician Career Satisfaction?","Inclusion Criteria:\n\n* Age: ≥18 years\n* Be a current licensed physician practicing at Methodist Health System( MHS )\n* Literate in English\n* Able and willing to provide consent\n\nExclusion Criteria:\n\n* \\\u003C18 years of age\n* Not a current licensed physician at MHS\n* Illiterate in English\n* Unable or unwilling to provide consent",{"count":137,"type":22},[119],"The aim of the study is to evaluate the impact of organizational interventions for physician development on wellbeing, and investigate wellbeing and other characteristics of physicians with and without formal leadership roles.",[348,349],"Leadership","Personality",{"date":297,"type":31},{"date":352,"type":31},"2023-12-01",{"date":354,"type":22},"2028-12",{"name":37,"class":38},{"id":357,"slug":358,"hasResults":12,"nctId":359,"briefTitle":360,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":364,"conditions":365,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":369,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":39},"100449162","evaluation-of-resection-techniques-for-pancreatic-tumors-100449162","NCT05128890","Evaluation of Resection Techniques for Pancreatic Tumors","Inclusion Criteria:\n\n* Patients that have undergone pancreatic or liver resection surgeries from January 2006 until December 2020 at Methodist Dallas Medical Center (MDMC)\n* Patients 18 years old or older\n\nExclusion Criteria:\n\n* Patients that have not undergone pancreatic resection surgeries\n* Patients under 18 years of age",{"count":363,"type":22},431,"The objective of this study is to compare open and minimally invasive pancreatic and liver resection techniques and analyze the different outcome variables from the clinical standpoint.\n\nThe plan is to investigate patient survival, length of stay, complication rates, operative time, transfusion rate, 30 and 90-day readmission rate, and hospital charges.",[366,367,368],"Surgery","Liver Tumor","Pancreas Tumor",{"date":297,"type":31},{"date":371,"type":31},"2016-04-16",{"date":373,"type":22},"2027-04-26",{"name":37,"class":38},{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":381,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":385,"conditions":386,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":389,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":395},"100369414","peptide-receptor-radionuclide-therapy-prrt-for-the-treatment-of-neuroendocrine-tumors-100369414","NCT04090034","Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors","Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine","PRRT","Inclusion Criteria:\n\n1. \\> 18 years of age\n2. Diagnosed with gastroenteropancreatic primary NET and has consented to undergo PRRT per the treating physician. Specifically:\n\n   * Will consider other primaries on a case by case basis if dotatate scan (+) and meet all other criteria.\n   * Metastatic or Locally Advanced AND Inoperable\n   * Clear disease progression on Octreotide over less than 3 years (RECIST 1.1)\n   * Presence of disease within 24 weeks as identified by PET\u002FCT scans with Ga-68 DOTATATE reporting the Krenning score for low-grade NET and\u002For PET\u002FCT scans with FDG for transformation to high-grade NET\n   * Well differentiated on path - Ki67 \\\u003C 20%\n   * Octreotide positive on pathology (if not documented, acceptable if PET\u002FCT imaging shows lesions with Ga-68 DOTATATE uptakeLabs:\n\n     * Cr. \\\u003C1.7\n     * Hgb \\>8\n     * WBC \\>2K\n     * Plt \\>75K\n     * Bili \\\u003C 3x normal limit\n   * No Octreotide within 30 days of administration.\n3. Willing and able to comply with the protocol requirements\n4. Able to comprehend and sign the Informed Consent Form in English.\n\nExclusion Criteria:\n\n* Do not meet the Study Inclusion Criteria laid out in section 6.3",{"count":384,"type":22},50,"The specific aim is of this study is to gain a better understanding of the patient characteristics, treatment responses, survival outcomes, and adverse events associated with PRRT in patients with gastroenteropancreatic primary NETs.",[387,388],"Neuroendocrine Tumors","Gastroenteropancreatic Neuroendocrine Tumor",{"date":297,"type":31},{"date":391,"type":31},"2024-03-28",{"date":393,"type":22},"2026-06-28",{"name":37,"class":38},2,{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":403,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":404,"conditions":405,"keywords":4,"overallStatus":407,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":4},"100602338","monitoring-the-response-of-combination-ursodiol-and-seladelpar-treatment-100602338","NCT07122206","Monitoring the Response of Combination Ursodiol and Seladelpar Treatment","Monitoring the Response of Combination Ursodiol and Seladelpar Treatment in Primary Biliary Cholangitis Using Invasive Markers","Inclusion Criteria:\n\n* Patients must have a confirmed diagnosis PBC as per established diagnostic criteria.\n* Adults aged 18 years and older.\n* Patients undergoing treatment with ursodiol (ursodeoxycholic acid) for PBC or who demonstrate intolerance to ursodiol due to side effects and persistent ALP \\> normal.\n* Patients undergoing treatment with seladelpar for PBC.\n* Patients must be willing and able to provide written informed consent for participation in the study.\n\nExclusion Criteria:\n\n* Patients that do not meet inclusion criteria.\n* Patients with other chronic liver diseases, such as hepatitis B, hepatitis C, non-alcoholic steatohepatitis (NASH), alcoholic liver disease, or other autoimmune liver diseases.\n* Patients who have undergone a liver transplant.\n* Presence of cirrhosis or hepatic decompensation at the time of study enrollment.\n* Patients with significant comorbid conditions that may interfere with the study outcomes, such as severe cardiovascular, renal, or pulmonary diseases.\n* Pregnant or breastfeeding women, due to potential risks to the fetus or infant.\n* Inability or unwillingness to comply with the study protocol, including scheduled visits, tests, and procedures.",{"count":48,"type":22},"This study aims to provide comprehensive insights into the therapeutic effects of combination treatment with ursodiol and seladelpar in PBC patients by assessing biochemical responses using biomarkers such as ALP and total bilirubin.",[406],"Primary Biliary Cholangitis","NOT_YET_RECRUITING","2025-08-07",{"date":410,"type":31},"2025-08-14",{"date":412,"type":22},"2025-08",{"date":414,"type":22},"2027-08",{"name":37,"class":38},{"id":417,"slug":418,"hasResults":12,"nctId":419,"briefTitle":420,"officialTitle":420,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":207,"enrollmentInfo":422,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":423,"conditions":424,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":39},"100569528","community-based-partnerships-efficacy-in-decreasing-injury-rates-at-night-in-dallas-tx-100569528","NCT06695416","Community-based Partnership's Efficacy in Decreasing Injury Rates At Night in Dallas, TX","Inclusion Criteria:\n\n* • Chief complaint or diagnosis associated with a trauma mechanism of injury: assault (i.e., gunshot wounds, knife wounds, general assault, or sexual assault), MVC, motorcycle\u002Fall-terrain vehicle collision (MCC), or auto-ped\u002Fbicycle collision\n\n  * Injury occurred between 6pm-6am\n  * Injury occurred in City of Dallas, TX\n\nExclusion Criteria:\n\n* • Injuries from mechanism other than assault, MVC, MCC, or auto-ped\u002Fbicycle\n\n  * Assault occurs outside of 6pm-6am window\n  * Assault occurred outside of Dallas city limits",{"count":154,"type":22},"According to the Centers for Disease Control and Prevention (CDC), \"88,000 people die every year due to alcohol-related issues including homicide, sexual assault, intimate partner violence, and suicide\". In the city of Dallas, violent crimes have decreased by roughly 4% in 2022 compared to 2021. Dallas Police Department (DPD) implemented changes in May 2021 to combat violent crimes.",[425,426],"Blood Alcohol Concentration","Drunk Driving","2024-11-18",{"date":429,"type":31},"2024-11-19",{"date":431,"type":31},"2023-04-28",{"date":433,"type":22},"2025-04-28",{"name":37,"class":38},{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":4,"eligibilityCriteria":441,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":442,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":444,"conditions":445,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":39},"100569751","evidence-based-approach-to-reduce-falls-in-adult-patients-100569751","NCT06698315","Evidence-based Approach to Reduce Falls in Adult Patients","Tailored Interventions for Patient Safety: an Evidence-based Approach to Reduce Falls in Adult Patients","Inclusion Criteria:\n\n* Adult (≥18 years) inpatients admitted for various medical-surgical conditions in 3 Medical unit at MRMC. All patients will be included in the project except those diagnosed with psychiatric conditions and cognitive impairments.\n\nExclusion Criteria:\n\n* Patients with psychiatric conditions and cognitive impairments will be excluded from the project. This assessment is routine.",{"count":443,"type":22},1000,"The project aims to promote patient safety and quality care by reducing preventable falls and falls with injuries using an evidence-based solution.",[446],"Falls with Injuries",{"date":448,"type":31},"2024-11-20",{"date":450,"type":31},"2024-07-23",{"date":452,"type":22},"2025-07",{"name":37,"class":38},{"id":455,"slug":456,"hasResults":12,"nctId":457,"briefTitle":458,"officialTitle":458,"acronym":4,"eligibilityCriteria":459,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":460,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":461,"conditions":462,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":464,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":39},"100569750","validation-of-compat-sf-spanish-translation-100569750","NCT06698302","Validation of COMPAT-SF Spanish Translation","Inclusion Criteria:\n\n* 18 years or older in age\n* Have a definite CP diagnosis and a stable pain pattern with no new interventions or medications in the last three months\n* Able to read and understand the study information in Spanish\n* Personally signed and dated ICF indicating that the subject has been informed of all pertinent aspects of the study\n* Subject is willing and able to comply with the scheduled questionnaires\n\nExclusion Criteria:\n\n* Subjects who do not meet the criteria in section 4.1",{"count":48,"type":22},"Prospective translation validation pilot study that will collect data from Spanish-speaking CP patients seen at Methodist Dallas Medical Center (MDMC) beginning June 2024 through July 2027, in order to validate a Spanish-translated COMPAT-SF instrument.",[463],"Chronic Pancreatitis",{"date":448,"type":31},{"date":466,"type":31},"2024-09-13",{"date":468,"type":22},"2026-09-13",{"name":37,"class":38},""]